Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by woundedkneeon Jul 23, 2023 2:13pm
167 Views
Post# 35553479

RE:RE:Just read

RE:RE:Just readKeep pushing Dan's narrative Mugsy. There were many investors bringing up liver concerns even before to move to the TSX. You're the one who is misleading here. It was liver concerns that brought this company down (without warning) and just maybe management had those same concerns in back of their mind. But no worries with the NEW ATE!! Management has that problem all in hand now. Probably just a coincidence, but there was a huge insider sale two or three weeks prior to that share collapse.  I remember too well when it closed at Approx. $4.50 and opened in the morning at approx 90 cents. And I was out 120 grand just like that. But Im a big boy and have moved on from that.
So here sits a stock trading at 45 cents that was touted to hit 15, 20 dollars or even higher. I'm not the only one who isn't buying this. All one has to do is look at the share price. You can change your name from arthritic to chronic, but you can't change the damage that's been done. The market has a long memory, as do I. And I do not remember doing any business with you sir, nor would I. I wouldn't doubt that you are part of management. If not why are you still here? GL

<< Previous
Bullboard Posts
Next >>